The authors have developed an LXR inverse agonist called TLC-2716 that is oral and restricted to the liver. This drug has shown efficacy in reducing triglyceride and cholesterol levels in preclinical models of dysmetabolism. The phase 1 study was conducted in healthy participants. TLC-2716 was well tolerated in her. The drug reduced plasma triglycerides. It also reduced postprandial residual cholesterol. These results suggest the potential of TLC-2716 in cardiovascular risk management. The article was published in Nature Medicine on January 16, 2026.